Abstract

We investigated whether the occurrence of neutralising streptokinase (SK) antibodies, as assessed by a new bedside test, was related to the effect of SK in acute myocardial infarction (AMI), assessed with continuous vectorcardiography (VCG). Twenty-eight patients with ST elevation, admitted ≤ 6 h after the onset of symptoms, treated with 1.5 MIU SK were included. The level of SK antibodies was assessed by the TAS Streptokinase Test Panel, measuring the lysis time of clotted fibrin in the sample. Clot lysis time was negatively correlated to ST vector magnitude (ST-VM) recovery at 90 min (r<sub>S</sub> = –0.40, p = 0.03), and clot lysis time was positively correlated to time to reperfusion, (r<sub>S</sub> = 0.42, p = 0.03). The predictive values of the test, however, were low. In conclusion, as the prediction of reperfusion in AMI after SK by the new test was poor, we cannot recommend it for clinical decision-making prior to the choice of the thrombolytic agent.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.